October 2018

Delta, Kelowna, BC – October 31, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of its series, Investorideas.com potcastsCM – cannabis news and stocks to watch plus insight from thought leaders and experts. Listen to the podcast: https://www.investorideas.com/Audio/Podcasts/2018/103118-StocksToWatch.mp3 Hear […]

by

TORONTO–(BUSINESS WIRE)–Oct 31, 2018–FSD Pharma Inc. (“ FSD Pharma ” or “ FSD ”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today announced the launch of a pilot clinical study in Pittsburgh, Pennsylvania, by its strategic RD partner, SciCann Therapeutics (“ SciCann ”). The study is designed to test the safety and efficacy of SciCann’s proprietary […]

by

This press release was orginally distributed by SBWire Arvada, CO — (SBWIRE) — 10/29/2018 — Unique to industrial hemp is the high amounts of phytocannabinoids sometimes referred to as CBD which is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid component found in cannabis sativa. Cannabidiols comprises up to 40% of the plant. CBD is […]

by

This press release was orginally distributed by SBWire Arvada, CO — (SBWIRE) — 10/29/2018 — Unique to industrial hemp is the high amounts of phytocannabinoids sometimes referred to as CBD which is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid component found in cannabis sativa. Cannabidiols comprises up to 40% of the plant. CBD is […]

by

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital. NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD). Medlab has received formal approval from the appropriate authority to proceed to stage II of […]

by

Medlab Clinical Ltd (ASX:MDC) has successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital. NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD). Medlab has received formal approval from the appropriate authority to proceed to stage II of […]

by

Fundamentals of US Regulatory Affairs, 10th Edition For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips. BUY NOW … read more at: https://www.raps.org/news-and-articles/news-articles/2018/10/recon-pfizer-novartis-team-up-to-test-nash-combo

by

In his letter, “What’s Medicine got to do with it?,” Dr. March Seabrook proposes that there is no scientific basis for the use of marijuana as medicine and this, combined with the fact that the FDA has not approved its use, makes it inappropriate to ask physicians to recommend it to patients. I have researched […]

by

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury […]

by

TORONTO, Oct. 26, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced its results for the fiscal year ended June 30, 2018.  The Audited Financial Statements and Management’s Discussion […]

by

Photo: Shutterstock.comA new pharmacokinetic and clinical study recently completed at Cornell suggests that 2 mg/kg of cannabidiol (CBD) oil twice daily can help increase comfort and activity in dogs with osteoarthritis. The abstract was submitted to the 2017 American College of Veterinary Surgeons Summit in Indianapolis and is pending peer review. The science The study […]

by

TORONTO — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers. This is a preliminary step in a broader strategy focused on identifying additional applications for Acerus’ proprietary nasal delivery […]

by

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers. This is a preliminary step in a broader strategy focused on identifying additional applications for Acerus’ proprietary nasal delivery technology, […]

by

This press release was orginally distributed by SBWire Alexandria, VA — (SBWIRE) — 10/24/2018 — Unique to industrial hemp is the high amounts of phytocannabinoids sometimes referred to as CBD which is an abbreviation for cannabidiol, a prominent naturally-occurring cannabinoid component found in cannabis sativa. Cannabidiols comprises up to 40% of the plant. CBD is […]

by

This has been a big year for “marijuana firsts.” We’ve witnessed a number of cannabis stocks move to reputable U.S. exchanges; stood back and watched the first cannabis-derived drug get approved by the U.S. Food and Drug Administration (FDA); and, of course, eagerly observed as Canada lifted the curtain on nine decades of recreational marijuana […]

by